- Home
- MIRM vs SGML Comparison
MIRM vs SGML Comparison
Compare MIRM & SGML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- SGML
- Stock Information
- Founded
- MIRM 2018
- SGML 2011
- Country
- MIRM United States
- SGML Brazil
- Employees
- MIRM N/A
- SGML N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- SGML Industrial Machinery/Components
- Sector
- MIRM Health Care
- SGML Industrials
- Exchange
- MIRM Nasdaq
- SGML Nasdaq
- Market Cap
- MIRM 1.9B
- SGML 1.6B
- IPO Year
- MIRM 2019
- SGML N/A
- Fundamental
- Price
- MIRM $44.50
- SGML $12.94
- Analyst Decision
- MIRM Strong Buy
- SGML Strong Buy
- Analyst Count
- MIRM 13
- SGML 2
- Target Price
- MIRM $57.00
- SGML $24.50
- AVG Volume (30 Days)
- MIRM 340.6K
- SGML 791.4K
- Earning Date
- MIRM 11-12-2024
- SGML 11-26-2024
- Dividend Yield
- MIRM N/A
- SGML N/A
- EPS Growth
- MIRM N/A
- SGML N/A
- EPS
- MIRM N/A
- SGML 0.08
- Revenue
- MIRM $307,028,000.00
- SGML $215,173,346.00
- Revenue This Year
- MIRM $73.07
- SGML $45.28
- Revenue Next Year
- MIRM $27.98
- SGML $90.35
- P/E Ratio
- MIRM N/A
- SGML $162.81
- Revenue Growth
- MIRM 112.14
- SGML N/A
- 52 Week Low
- MIRM $23.14
- SGML $8.47
- 52 Week High
- MIRM $48.89
- SGML $34.31
- Technical
- Relative Strength Index (RSI)
- MIRM 65.32
- SGML 46.06
- Support Level
- MIRM $41.09
- SGML $12.41
- Resistance Level
- MIRM $48.89
- SGML $14.77
- Average True Range (ATR)
- MIRM 2.16
- SGML 0.99
- MACD
- MIRM 0.57
- SGML -0.14
- Stochastic Oscillator
- MIRM 59.09
- SGML 37.21
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About SGML Sigma Lithium Corporation
Sigma Lithium Corp is dedicated to powering the next generation of electric vehicle batteries with environmentally sustainable and high-purity lithium. The company is in construction at its wholly owned Grota do Cirilo Project in Brazil, one of the highest-grade hard rock lithium spodumene deposits in the Americas.